| Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature. | |
| | |
MedLine Citation:
|
PMID: 19335434 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The development of vitiligo has been associated with an improved clinical response in melanoma patients. METHODS: We report a case of vitiligo associated with a novel antisurvivin drug and review the literature to determine the pathogenesis of vitiligo occurring during melanoma treatment. RESULTS: A 78-year-old man with stage IV malignant melanoma developed vitiligo after the first therapeutic cycle of a novel antisurvivin drug. Although his vitiligo remained static, his melanoma continued to progress and he died in 8 months. A review of the literature demonstrates a relationship between vitiligo development and improved clinical response in many melanoma cases treated with immunotherapy; however, the relationship may depend on the type of treatment. CONCLUSIONS: Understanding complex immune responses in vitiliginous skin and melanoma sites is important in order to interpret the development of vitiligo occurring during melanoma treatment. |
| | |
Authors:
|
Mayumi Fujita; Whitney A High; Shabnam Asgari; Karl D Lewis; Rene Gonzalez |
Related Documents
:
|
10331574 - Extramammary paget's disease with aggressive behavior: a report of two cases. 19365884 - Gastric metastasis of malignant fibrous histiocytoma presenting as gastrointestinal ble... 2537714 - Malignant fibrous histiocytoma of the anal canal. report of a case and review of the li... 16173314 - Mucosal melanoma: case report and review. 3139794 - Synovial chondromatosis of the temporomandibular joint. report of a case and review of ... 5289714 - Gastroenteritis due to salmonella subgenus 3 (arizona). a second case diagnosed in brit... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: International journal of dermatology Volume: 48 ISSN: 1365-4632 ISO Abbreviation: Int. J. Dermatol. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-01 Completed Date: 2009-07-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0243704 Medline TA: Int J Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 426-30 Citation Subset: IM |
Affiliation:
|
Department of Dermatology and Division of Medical Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80010-7163, USA. mayumi.fujita@ucdenver.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Agents / administration & dosage, adverse effects* Humans Imidazoles / administration & dosage, adverse effects* Male Melanoma / drug therapy* Microtubule-Associated Proteins / antagonists & inhibitors* Naphthoquinones / administration & dosage, adverse effects* Skin Neoplasms / drug therapy* Vitiligo / chemically induced*, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/BIRC5 protein, human; 0/Imidazoles; 0/Microtubule-Associated Proteins; 0/Naphthoquinones; 0/YM 155 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Are we aware of all complications following body piercing procedures?
Next Document: Effects of tacrolimus ointment on the expression of substance P, nerve growth factor, and neurotroph...